| Id: | acc2430 |
| Group: | 2sens |
| Protein: | NFKBIA |
| Gene Symbol: | NFKBIA |
| Protein Id: | P25963 |
| Protein Name: | IKBA_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser32 |
| Site Sequence: | ERLLDDRHDSGLDSMKDEEYE |
| Disease Category: | Cancer |
| Disease: | Myeloma |
| Disease Subtype: | multiple myeloma |
| Disease Cellline: | U266 |
| Disease Info: | |
| Drug: | PS-1145 |
| Drug Info: | "PS-1145 is a specific inhibitor of IκB kinase (IKK) with an IC50 of 88 nM, primarily used in research to block NF-κB signaling pathways and studied for its potential effects in inflammatory and oncological contexts. " |
| Effect: | modulate |
| Effect Info: | Drug inhibits protein phosphorylation to suppress tumors. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 11872748 |
| Sentence Index: | 11872748_5-6 |
| Sentence: | "Our studies demonstrate that PS-1145 and PS-341 block TNFalpha-induced NF-kappaB activation in a dose- and time-dependent fashion in MM cells through inhibition of IkappaBalpha phosphorylation and degradation of IkappaBalpha, respectively. Dexamethasone (Dex), which up-regulates IkappaBalpha protein, enhances blockade of NF-kappaB activation by PS-1145." |
Sequence & Structure:
MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| NFKBIA-Ser32 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
| T | 32 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
